Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024
MarketsandMarkets forecasts the Cancer/Tumor Profiling market to grow from USD 7.56 billion in 2019 to USD 12.47 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period. The increasing incidence of cancer across the globe and the increasing use of biomarkers in tumor profiling are the primary growth drivers for this market. In addition, the increase in cancer research and funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market. The objective of the report is to define, describe, and forecast the cancer/tumor profiling market size based on technology, cancer type, biomarker type, application, and region.
By technology, the NGS segment is expected to grow at the highest growth rate during the forecast period
Among the technologies used in cancer/tumor profiling, the next-generation sequencing (NGS) segment is expected to grow at the highest CAGR during the forecast period. The benefits of effectively exploring genetic alterations in a wide range of cancers and the identification of a number of differentially expressed genes and genetic/epigenetic variants as potential targets aid in the development of new biomarkers for early diagnosis of the disease. These factors are supporting the adoption of the NGS technology in molecular profiling of various cancer genes, propelling market growth.
By cancer type, the lung cancer segment to record the highest CAGR during the forecast period
The lung cancer segment is expected to witness a faster growth rate in this market. The increasing incidence of lung cancer worldwide and the increasing need for early diagnosis are supporting the growth of this segment. This in turn is propelling the molecular profiling market.
By biomarker type, the protein biomarkers segment to record the highest CAGR during the forecast period
Among the biomarkers used in cancer/tumor profiling, the protein biomarkers segment is expected to grow at the highest CAGR during the forecast period, majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase the enormous potential for directing personalized cancer therapy and treatment monitoring.
By application, the research applications segment accounted for the largest share of the market
The research applications segment accounted for the largest share of the cancer tumor profiling market. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the increasing funding for cancer research is propelling the growth of the market.
North America to account for the largest market size during the forecast period.
North America is expected to hold the largest market size in the cancer tumor profiling market during the forecast period, followed by the European region. The highest market share of North America can be attributed to the increasing investments for the discovery and development of biomarkers through molecular profiling, growing demand for personalized therapeutics, rising adoption of advanced omics technologies for cancer research, and the increasing use of biomarkers for drug development with regard to the increasing incidence of cancer. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment. On the other hand, the Asia Pacific market is expected to witness the highest growth during the forecast period, primarily due to the high incidence of cancer, growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics.
Market Dynamics
Driver: Increasing use of biomarkers in cancer profiling
The last decade has seen significant advances in the development of biomarkers in oncology that play a critical role in understanding molecular and cellular mechanisms which drive tumor initiation, maintenance, and progression. Clinical molecular diagnostics and biomarker discoveries in oncology are advancing rapidly and have fueled the development of novel drug targets and new treatment strategies. Biomarkers help in understanding the mechanism of action of a drug, investigating the efficacy and toxicity signals at an early stage of pharmaceutical development, and identifying patients likely to respond to treatment. Additionally, biomarkers are widely expected to be used as a tool for disease diagnosis, personalized medication, and surrogate endpoints in clinical research. The growth in basic and clinical research in various therapeutic areas in the past years has drawn attention towards potential new biomarkers which are more sensitive and specific than the conventional ones. Due to the high prevalence of cancer, many pharmaceutical and diagnostic manufacturers are developing new biomarkers for cancer types such as breast, lung, colorectal, melanoma, and leukemia. These biomarkers help in identifying gene mutations that cause cancer. Recent advances in multiplex genotyping technologies and high-throughput genomic profiling by NGS have made the rapid and comprehensive analysis of the cancer genome of individual patients possible, even with a small amount of biopsy material.
Restraint: High capital investment
Within the current paradigm of personalized medicine or precision medicine, many research efforts are aimed at identifying novel biomarkers. Significant capital investments are required for the discovery, development, and validation of biomarkers used in cancer detection and prognosis. Once a candidate biomarker is developed, the evidence is required for its adoption in the clinical field. The discovery of candidate biomarkers far outpaces the current ability to validate them. Akin to clinical trials for pharmaceuticals, translational research is a long and complex trajectory requiring large financial investments, and results in the rejection of a number of biomarker candidates. An estimated cost for the development and commercialization of a new biomarker-based diagnostic technology exceeds over USD 100 million. Such huge investments to run clinical trials and address stringent regulatory requirements not only affects the ability of small companies to develop biomarkers but also severely affects innovation. This is a major factor restraining the growth of the biomarkers market and other related markets such as diagnostics (in vitro diagnostics or companion diagnostics) and personalized medicine.
Opportunity: Growing need for point-of-car diagnostics
Currently, most diagnostic disease testing is carried out in centralized or hospital-based laboratories by using expensive equipment that requires highly trained personnel to operate. The need for the early diagnosis and monitoring of the progress of cancers are limited due to the lack of adequate screening tools, along with the costly, time-consuming, and invasive nature of these tests. This has led to the possibility of developing fast, reliable, and noninvasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Ultrasensitive and precise point-of-care cancer diagnostic tools are required for the early detection and screening of cancer biomarkers with accuracy and specificity of diagnosis. The incorporation of well-known biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Recent advances in nano- and microfabrication-based technologies integrated with different sensing platforms are accelerating the development of rapid, low-cost, and reliable point-of-care cancer diagnostic devices. A new trend for miniaturization has been observed in the POC testing industry with the introduction of lab-on-a-chip devices or miniaturized total analysis systems (μTAS). The need to reduce costs associated with tests by decreasing the consumption of reagents, shortening analysis times, and increasing efficiency are driving the need for miniaturization in POC devices.
Challenge: Poor regulatory and reimbursement scenario
The acceptance of biomarker-based tests in clinical applications requires evidence of the biomarkers clinical validity and utility. This is important not just only to help physicians in the decision-making process but also to achieve regulatory approvals and reimbursements for tests. However, amassing the data necessary to show clinical validity and utility may be a time-consuming and expensive process, which is further complicated by the lack of standard regulations. Moreover, in most OECD countries, regulatory procedures are not well-adapted with new molecular diagnostic tests used for cancer/tumor profiling. Many of the current regulatory systems have been developed for simple diagnostic tests and are not well-suited for novel biomarker-based diagnostics producing complex data that requires high data analysis and interpretation. Furthermore, obtaining coverage and reimbursement is also one of the major obstacles to the commercial adoption of new cancer biomarker tests. Most governments in the Asian market neither reimburse the use of biomarkers nor provide research funding for the same. Diagnostic companies face difficulties in seeking reimbursements for particular companion diagnostic tests used in cancer/tumor profiling. The reimbursement levels for diagnostics set by the CMS (Centers for Medicare and Medicaid Services) do not adequately reflect their actual cost or clinical value.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
20172024 |
|
Base year considered |
2018 |
|
Forecast period |
20192024 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Technology, Cancer Type, Biomarker Type, Application, and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
|
Companies covered |
Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US). |
The research report categorizes the cancer/tumor profiling market to forecast the revenues and analyze the trends in each of the following sub-segments:
Cancer/Tumor Profiling Market, by Technology
- Immunoassays
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- In-Situ Hybridization (ISH)
- Microarrays
- Mass Spectrometry
- Others
Cancer/Tumor Profiling Market, by Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Cancers
Cancer/Tumor Profiling Market, by Biomarker Type
- Genetic Biomarkers
- Protein Biomarkers
- Other Biomarkers
Cancer/Tumor Profiling Market, by Application
- Research
- Biomarker discovery
- Personalized Medicine
- Clinical
- Diagnostics
- Prognostics
- Screening
- Treatment & Monitoring
Cancer/Tumor Profiling Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players
- Illumina, Inc. (US)
- QIAGEN N.V. (Germany)
- NeoGenomics Laboratories, Inc. (US)
- HTG Molecular Diagnostics, Inc. (US)
- Sysmex Corporation (Japan)
Illumina is a global manufacturer of sequencing- and array-based solutions for genetic and genomic analysis and holds a leading position in the cancer/tumor profiling market. Owing to its strong sales and distribution network, the company has a significant global footprint. The company leverages the advantage of an established brand name in the market. With a strong global presence, Illumina is constantly involved in product and technological innovations for the cancer/tumor profiling market, which has led to an increase in the companys overall revenue. It focuses on acquiring new consumers through expansions, partnerships, and collaborations, along with introducing advanced products in the market. In line with this, in the last three years, the company entered into various business alliances and has undertaken a number of product launches.
Recent Developments
- In May 2019, Waters QIAGEN N.V. (Germany) launched its therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) as a companion diagnostic to aid in identifying breast cancer patients.
- In March 2019, HTG Molecular Technologies, Inc. (US) launched the HTG EdgeSeq Mouse mRNA Tumor Response Panel in the US and Europe.
- In May 2019, QIAGEN and leading UK-based organizations launched APIS Assay Technologies Ltd., a company that aims to improve the success rate of biomarker commercialization.
- In May 2019, Caris completed the acquisition of Phamatech, Inc., a company with a large research-ready oncology network with the aim of expanding industry-leading clinical trials and also undertake precision oncology trials.
- In February 2019, Sysmex Corporation (Japan) OGT expanded its Cytocell operations with a move to a new facility in Cambridge, UK. The companys FISH probe brand will be moved to this facility, which will aid the expansion of the sales volumes and sales growth.
Critical questions the report answers:
- Where will all these developments take the industry in the long term?
- What are the upcoming trends in the cancer/tumor profiling market?
- Which segment provides the most opportunity for growth?
- Who are the leading vendors operating in this market?
- What are the opportunities for new market entrants?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 25)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
Figure 1 Cancer/Tumor Profiling Market
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
1.6 Limitations
2 Research Methodology (Page No. - 28)
2.1 Research Approach
Figure 2 Research Design
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
Figure 3 Breakdown of Primary Interviews: By Company Type, Designations, and Region
2.1.2.3 Key Industry Insights
2.2 Market Size Estimation
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
2.3 Data Triangulation Approach
Figure 6 Data Triangulation Methodology
2.4 Assumptions for the Study
3 Executive Summary (Page No. - 36)
Figure 7 Cancer/Tumor Profiling Market, By Technology, 2019 vs 2024 (USD Million)
Figure 8 Cancer/Tumor Profiling Market, By Cancer Type, 2019 vs 2024 (USD Million)
Figure 9 Cancer/Tumor Profiling Market, By Biomarker Type, 2019 vs 2024 (USD Million)
Figure 10 Cancer/Tumor Profiling Market, By Application, 2019 vs 2024 (USD Million)
Figure 11 Geographical Snapshot of the Cancer/Tumor Profiling Market
4 Premium Insights (Page No. - 41)
4.1 Cancer/Tumor Profiling: Market Overview
Figure 12 Increasing Demand for Personalized Medicine to Drive Market Growth
4.2 Cancer/Tumor Profiling Market: Geographic Growth Opportunities
Figure 13 China to Register the Highest Growth in the Cancer/Tumor Profiling Market During the Forecast Period
4.3 Regional Mix: Cancer/Tumor Profiling Market (20192024)
Figure 14 APAC to Witness the Highest Growth During the Forecast Period (20192024)
4.4 Cancer/Tumor Profiling Market: Developed vs Developing Markets (2019 vs 2024)
Figure 15 Developing Markets to Register A Higher Growth Rate Between 2019 & 2024
5 Market Overview (Page No. - 45)
5.1 Introduction
5.2 Market Dynamics
Figure 16 Cancer/Tumor Profiling Market: Drivers, Restraints, Opportunities, and Challenges
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence of Cancer
Figure 17 Global Cancer Incidence, 20082030
5.2.1.2 Increasing Use of Biomarkers in Cancer Profiling
5.2.1.3 Increasing Cancer Research and Funding
5.2.1.4 Technological Advancements
Table 1 Market Drivers: Impact Analysis
5.2.2 Market Restraints
5.2.2.1 High Capital Investment
5.2.2.2 Technical Issues With Sample Collection and Storage
Table 2 Market Restraints: Impact Analysis
5.2.3 Market Opportunities
5.2.3.1 Increasing Demand for Personalized Medicine
Figure 18 Launch of Personalized Medicine Products, 20082016
5.2.3.2 Growing Need for Point-of-Care Diagnostics
Table 3 Market Opportunities: Impact Analysis
5.2.4 Market Challenges
5.2.4.1 Low Biomarker Discovery-To-Approval Ratio
5.2.4.2 Poor Regulatory and Reimbursement Scenario
Table 4 Market Challenges: Impact Analysis
6 Industry Insights (Page No. - 54)
6.1 Introduction
6.2 Industry Trends
Figure 19 Increasing Use of Integrated Omics Data and Growing Focus on Liquid Biopsy Tests are Key Market Trends
6.2.1 Integration of Omics Data
6.2.2 Advances in Liquid Biopsy
6.2.3 Organoids for Personalized Medicine
7 Cancer/Tumor Profiling Market, By Technology (Page No. - 57)
7.1 Introduction
Figure 20 Immunoassays to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 5 Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
7.2 Immunoassays
7.2.1 Immunoassay Tests Identify and Assess the Progression of Disease, Thereby Providing Information Vital for Better Therapeutic Choices
Table 6 Cancer/Tumor Profiling Market for Immunoassays, By Country, 20172024 (USD Million)
7.3 Next-Generation Sequencing
7.3.1 Advances in NGS Multiplexing Capabilities Enable One Assay to Provide A Complete Tumor Molecular Profile
Table 7 Cancer/Tumor Profiling Market for Next-Generation Sequencing, By Country, 20172024 (USD Million)
7.4 Polymerase Chain Reaction
7.4.1 Real-Time PCR Helps in the Quantification of Low-Copy Transcripts, Aiding Biomarker Identification
Table 8 Cancer/Tumor Profiling Market for Polymerase Chain Reaction, By Country, 20172024 (USD Million)
7.5 in Situ Hybridization
7.5.1 FISH is the Gold Standard for Evaluating Some Key Biomarkers and Plays A Critical Role in Guiding Targeted Therapies
Table 9 Cancer/Tumor Profiling Market for in Situ Hybridization, By Country, 20172024 (USD Million)
7.6 Microarrays
7.6.1 Microarrays are Widely Adopted in Diagnostics as They Aid in Predicting the Recurrence of Cancer After Treatment
Table 10 Cancer/Tumor Profiling Market for Microarrays, By Country, 20172024 (USD Million)
7.7 Mass Spectrometry
7.7.1 Technological Advancements are Supporting the Adoption of This Technology for Sensitive, Reliable, and Rapid Diagnosis
Table 11 Cancer/Tumor Profiling Market for Mass Spectrometry, By Country, 20172024 (USD Million)
7.8 Other Technologies
Table 12 Cancer/Tumor Profiling Market for Other Technologies, By Country, 20172024 (USD Million)
8 Cancer/Tumor Profiling Market, By Cancer Type (Page No. - 71)
8.1 Introduction
Figure 21 Breast Cancer Segment to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 13 Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
8.2 Breast Cancer
8.2.1 Breast Cancer is the Most Common Cancer Found Among Women
Table 14 Cancer/Tumor Profiling Market for Breast Cancer, By Country, 20172024 (USD Million)
8.3 Lung Cancer
8.3.1 Molecular Characterization of Tumors Using NGS has is A Key Tool for the Clinical Management of Nsclc Patients
Figure 22 Global Lung Cancer Incidence, 2012-2030
Table 15 Cancer/Tumor Profiling Market for Lung Cancer, By Country, 20172024 (USD Million)
8.4 Colorectal Cancer
8.4.1 IHC, PCR, Microarrays, and Imaging Technologies are Major Technologies Used in Colorectal Diagnostics
Figure 23 Colorectal Cancer Incidence Rate, Key Countries (2018)
Table 16 Cancer/Tumor Profiling Market for Colorectal Cancer, By Country, 20172024 (USD Million)
8.5 Prostate Cancer
8.5.1 Prostate-Specific Antigen is A Widely Used FDA-Approved Biomarker for Prostate Cancer Screening
Table 17 Cancer/Tumor Profiling Market for Prostate Cancer, By Country, 20172024 (USD Million)
8.6 Melanoma
8.6.1 RT-QPCR is Generally Utilized to Conduct Molecular Profiling and Analyze Biomarkers in Melanomas
Table 18 Cancer/Tumor Profiling Market for Melanoma, By Country, 20172024 (USD Million)
8.7 Other Cancers
Table 19 Cancer/Tumor Profiling Market for Other Cancers, By Country, 20172024 (USD Million)
9 Cancer/Tumor Profiling Market, By Biomarker Type (Page No. - 83)
9.1 Introduction
Figure 24 Genetic Biomarkers to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 20 Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
9.2 Genetic Biomarkers
9.2.1 Genetic Biomarkers are Frequently Used in Clinical Practice for Diagnosis and Prognosis
Table 21 Cancer/Tumor Profiling Market for Genetic Biomarkers, By Country, 20172024 (USD Million)
9.3 Protein Biomarkers
9.3.1 Proteomic Methods Showcase Significant Promise for the Discovery of Novel Biomarkers
Table 22 Cancer/Tumor Profiling Market for Protein Biomarkers, By Country, 20172024 (USD Million)
9.4 Other Biomarkers
Table 23 Cancer/Tumor Profiling Market for Other Biomarkers, By Country, 20172024 (USD Million)
10 Cancer/Tumor Profiling Market, By Application (Page No. - 90)
10.1 Introduction
Figure 25 Research Applications to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 24 Cancer/Tumor Profiling Market, By Application, 20172024 (USD Million)
10.2 Research Applications
Table 25 Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
10.2.1 Biomarker Discovery
10.2.1.1 Biomarkers are Being Exploited for the Development of Personalized Or Precision Medicine
Table 26 Cancer/Tumor Profiling Market for Biomarker Discovery, By Country, 20172024 (USD Million)
10.2.2 Personalized Medicine
10.2.2.1 The Field of Personalized Medicine is Witnessing Rapid Growth in the Area of Oncology
Table 27 Cancer/Tumor Profiling Market for Personalized Medicine, By Country, 20172024 (USD Million)
10.3 Clinical Applications
Table 28 Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
10.3.1 Diagnostics
10.3.1.1 Tumor Profiling is Rapidly Gaining Momentum in the Area of Diagnostics
Table 29 Cancer/Tumor Profiling Market for Diagnostics, By Country, 20172024 (USD Million)
10.3.2 Prognostics
10.3.2.1 Advancements in Molecular Biology are Aiding the Uptake of Tumor Profiling in This Segment
Table 30 Cancer/Tumor Profiling Market for Prognostics, By Country, 20172024 (USD Million)
10.3.3 Monitoring & Treatment
10.3.3.1 Multiplatform Profiling Analyses are Gaining Recognition for Monitoring and Treatment Among Cancer Patients
Table 31 Cancer/Tumor Profiling Market for Monitoring & Treatment, By Country, 20172024 (USD Million)
10.3.4 Screening
10.3.4.1 Screening Tests Help in Deciding If Diagnostic Tests are Required By the Patient
Table 32 Cancer/Tumor Profiling Market for Screening, By Country, 20172024 (USD Million)
11 Cancer/Tumor Profiling Market, By Region (Page No. - 101)
11.1 Introduction
Figure 26 Cancer/Tumor Profiling Market:Geographic Snapshot (2018)
Table 33 Cancer/Tumor Profiling Market, By Region, 20172024 (USD Million)
11.2 North America
Figure 27 North America: Cancer/Tumor Profiling Market Snapshot
Table 34 North America: Cancer/Tumor Profiling Market, By Country, 20172024 (USD Million)
Table 35 North America: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 36 North America: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 37 North America: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 38 North America: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 39 North America: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.2.1 US
11.2.1.1 US Dominates the North American Cancer/Tumor Profiling Market
Table 40 US: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 41 US: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 42 US: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 43 US: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 44 US: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.2.2 Canada
11.2.2.1 Growing Public-Private Partnerships to Promote Proteomics Research are Expected to Drive the Market in Canada
Table 45 Canada: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 46 Canada: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 47 Canada: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 48 Canada: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 49 Canada: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3 Europe
Figure 28 Europe: Cancer/Tumor Profiling Market Snapshot
Table 50 Europe: Cancer/Tumor Profiling Market, By Country, 20172024 (USD Million)
Table 51 Europe: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 52 Europe: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 53 Europe: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 54 Europe: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 55 Europe: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.1 Germany
11.3.1.1 Advancements Proteomics and Genomics Research are Expected to Drive Market Growth
Table 56 Germany: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 57 Germany: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 58 Germany: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 59 Germany: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 60 Germany: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.2 UK
11.3.2.1 Growth in the Life Science Industry and the Increase in Academia-Industry Partnerships Will Be the Key Factors Driving the Market
Table 61 UK: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 62 UK: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 63 UK: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 64 UK: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 65 UK: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.3 France
11.3.3.1 Growth in This Market is Primarily Driven By Increasing Investments in Life Science R&D for Infrastructural Development
Table 66 France: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 67 France: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 68 France: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 69 France: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 70 France: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.4 Italy
11.3.4.1 Increasing Investment in Cancer and Translational Research is Expected to Propel Market Growth During the Forecast Period
Table 71 Italy: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 72 Italy: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 73 Italy: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 74 Italy: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 75 Italy: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.5 Spain
11.3.5.1 Rising Incidence of Cancer and Increasing Focus on Cancer Biomarkers By Various Medical Societies to Support Market Growth in Spain
Table 76 Spain: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 77 Spain: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 78 Spain: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 79 Spain: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 80 Spain: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.6 Rest of Europe
Table 81 RoE: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 82 RoE: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 83 RoE: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 84 RoE: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 85 RoE: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4 Asia Pacific
Figure 29 Asia Pacific: Cancer/Tumor Profiling Market Snapshot
Table 86 Asia Pacific: Cancer/Tumor Profiling Market, By Country, 20172024 (USD Million)
Table 87 Asia Pacific: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 88 Asia Pacific: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 89 Asia Pacific: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 90 Asia Pacific: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 91 Asia Pacific: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.1 Japan
11.4.1.1 Large Number of Research Initiatives Towards the Development of Precision Medicine Supporting Market Growth in Japan
Table 92 Japan: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 93 Japan: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 94 Japan: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 95 Japan: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 96 Japan: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.2 China
11.4.2.1 China has the Fastest-Growing Research Sector in the APAC Region
Table 97 China: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 98 China: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 99 China: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 100 China: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 101 China: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.3 India
11.4.3.1 Increasing Pharma R&D and Government Funding in the Biotechnology Industry are the Major Factors Driving Market Growth in India
Table 102 India: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 103 India: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 104 India: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 105 India: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 106 India: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.4 Rest of Asia Pacific
Table 107 RoAPAC: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 108 RoAPAC: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 109 RoAPAC: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 110 RoAPAC: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 111 RoAPAC: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.5 Latin America
11.5.1 Growing Proteomics Research in the Field of Cancer Along With the Rising Use of Advanced Techniques to Drive Market Growth
Table 112 Latin America: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 113 Latin America: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 114 Latin America: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 115 Latin America: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 116 Latin America: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.6 Middle East & Africa
11.6.1 Growing Genomics and Proteomics Research and Increasing Research Collaborations are Expected to Support Market Growth
Table 117 Middle East & Africa: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 118 Middle East & Africa: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 119 Middle East & Africa: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 120 Middle East & Africa: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 121 Middle East & Africa: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
12 Competitive Landscape (Page No. - 161)
12.1 Overview
Figure 30 Collaborations, Partnerships, and AgreementsKey Growth Strategy Adopted By Market Players From 2016 to May 2019
12.2 Competitive Leadership Mapping
12.2.1 Visionary Leaders
12.2.2 Innovators
12.2.3 Dynamic Differentiators
12.2.4 Emerging Companies
Figure 31 Cancer/Tumor Profiling Market: Competitive Leadership Mapping (2018)
12.3 Competitive Situation and Trends
12.3.1 Product Launches, Approvals, and Enhancements
Table 122 Product Launches, 20162019
12.3.2 Expansions
Table 123 Expansions, 20162019
12.3.3 Acquisitions
Table 124 Acquisitions, 20162019
12.3.4 Other Strategies
Table 125 Other Strategies, 20162019
13 Company Profiles (Page No. - 168)
(Business Overview, Products and Services Offered, Recent Developments, SWOT Analysis, and MnM View)*
13.1 Illumina, Inc.
Figure 32 Illumina, Inc.: Company Snapshot (2018)
13.2 Qiagen N.V.
Figure 33 Qiagen N.V.: Company Snapshot (2018)
13.3 Neogenomic Laboratories, Inc.
Figure 34 Neogenomic Laboratories, Inc.: Company Snapshot (2018)
13.4 Sysmex Corporation
Figure 35 Sysmex Corporation: Company Snapshot (2018)
13.5 HTG Molecular Diagnostics, Inc.
Figure 36 HTG Molecular Diagnostics, Inc.: Company Snapshot (2018)
13.6 Helomics Corporation
13.7 Genomic Health, Inc.
Figure 37 Genomic Health, Inc.: Company Snapshot (2018)
13.8 Caris Life Sciences
13.9 Nanostring Technologies, Inc.
Figure 38 Nanostring Technologies, Inc.: Company Snapshot (2018)
13.10 Ribomed Biotechnologies, Inc.
13.11 Guardant Health, Inc.
Figure 39 Guardant Health, Inc.: Company Snapshot (2018)
13.12 Foundation Medicine
Figure 40 Foundation Medicine: Company Snapshot (2018)
* Business Overview, Products and Services Offered, Recent Developments, SWOT Analysis, and MnM View Might Not Be Captured in Case of Unlisted Companies.
14 Appendix (Page No. - 219)
14.1 Insights of Industry Experts
14.2 Market Sizing & Validation Approach
14.3 Discussion Guide
14.4 Knowledge Store: Marketsandmarkets Subscription Portal
14.5 Available Customizations
14.6 Related Reports
14.7 Author Details
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of cancer/tumor profiling market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology & innovation directors, and related key executives from various key companies and organizations operating in cancer/tumor profiling market. Primary sources from the demand side include scientists, pathologists, doctors, and purchase managers of research institutes, government & private hospitals, biotechnology industries, and academic institutes. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, by cancer type, by biomarker type, by application, and region).
Data Triangulation
After arriving at the market size, cancer/tumor profiling market was divided into several segments and subsegments. The data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, wherever applicable.
Objectives of the Study
- To define, describe, segment, and forecast global cancer/tumor profiling market by technology, cancer type, biomarker type, application, and region.
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
- To analyze micro-markets with respect to individual growth trends, prospects, and contributions to overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market in five main regions along with their respective key countries (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa)
- To profile key players in global market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions; new product launches, enhancements and approvals; expansions; collaborations, partnerships, & agreements; and R&D activities of the leading players in market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
Geographic Analysis
- A further breakdown of the Latin America cancer/tumor profiling market into Brazil, Mexico, and Rest of Latin America
- A further breakdown of European market into Switzerland, Netherlands, and Rest of Europe.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cancer/Tumor Profiling Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Cancer/Tumor Profiling Market